Blood Neoplasia最新文献_第2页

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions T 细胞淋巴细胞淋巴瘤与 T 细胞急性淋巴细胞白血病的比较：相似的亚型和不同的融合

Blood Neoplasia Pub Date : 2024-09-01 DOI: 10.1016/j.bneo.2024.100029

Emma Kroeze , Michelle M. Kleisman , Rico Hagelaar , Reno S. Bladergroen , Lennart A. Kester , Marijn A. Scheijde-Vermeulen , Freerk van Dijk , Jules P. P. Meijerink , Roland P. Kuiper ∗ , Jan L. C. Loeffen ∗

引用次数: 0

Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML 靶向 SLFN11 调控通路可恢复急性髓细胞白血病化疗敏感性

Blood Neoplasia Pub Date : 2024-08-28 DOI: 10.1016/j.bneo.2024.100037

Sara H. Small , Ricardo E. Perez , Elspeth M. Beauchamp , Aneta H. Baran , Stephen D. Willis , Mariafausta Fischietti , Michael Schieber , Masha Kocherginsky , Diana Saleiro , Leonidas C. Platanias

{"title":"Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML","authors":"Sara H. Small , Ricardo E. Perez , Elspeth M. Beauchamp , Aneta H. Baran , Stephen D. Willis , Mariafausta Fischietti , Michael Schieber , Masha Kocherginsky , Diana Saleiro , Leonidas C. Platanias","doi":"10.1016/j.bneo.2024.100037","DOIUrl":"10.1016/j.bneo.2024.100037","url":null,"abstract":"<div><h3>Abstract</h3><div>Chemoresistance represents an ongoing challenge in treating patients with acute myeloid leukemia (AML), and a better understanding of the resistance mechanisms can lead to the development of novel AML therapies. Here, we demonstrated that low expression of the DNA damage response gene Schlafen 11 (<em>SLFN11</em>) correlates with poor overall survival and worse prognosis in patients with AML. Moreover, we showed that SLFN11 plays an essential role in regulating chemotherapy sensitivity in AML. AML cells with suppressed levels of SLFN11 do not undergo apoptosis in response to cytarabine because of aberrant activation of the Ataxia telangiectasia and Rad3-related protein (ATR)/Checkpoint kinase 1 (Chk1) pathway, allowing for DNA damage repair, whereas sensitivity to cytarabine can be restored by inhibiting the ATR pathway. Importantly, <em>SLFN11</em> knockout AML cells retain sensitivity to hypomethylating agents and the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Altogether, these results reveal <em>SLFN11</em> as an important regulator and predictor of chemotherapy sensitivity in AML and suggest that targeting pathways suppressed by SLFN11 may offer potential combination therapies to enhance and optimize chemotherapy responses in AML.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142573254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation 实体器官移植后小儿外周T细胞淋巴瘤的临床和病理特征

Blood Neoplasia Pub Date : 2024-08-28 DOI: 10.1016/j.bneo.2024.100039

Jinjun Cheng , Rachel Mariani , Jyotinder Nain Punia , Marimar de la Cruz Bonilla , Pichayut Nithagon , Metin Ozdemirli , Wen Shuai , Larry Wang , Oussama Abla , Shunyou Gong

引用次数: 0

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia 成人急性髓性白血病患者使用低甲基化药物和 Venetoclax 后的强化化疗

Blood Neoplasia Pub Date : 2024-08-28 DOI: 10.1016/j.bneo.2024.100038

Kuo-Kai Chin ∗ , Yannis Valtis ∗ , Andriy Derkach , Meira Yisraeli Salman , Leora Boussi , Jenna Ciervo , Mark B. Geyer , Jae H. Park , Martin S. Tallman , Jacob L. Glass , Aaron D. Goldberg , Eytan M. Stein

{"title":"Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia","authors":"Kuo-Kai Chin ∗ , Yannis Valtis ∗ , Andriy Derkach , Meira Yisraeli Salman , Leora Boussi , Jenna Ciervo , Mark B. Geyer , Jae H. Park , Martin S. Tallman , Jacob L. Glass , Aaron D. Goldberg , Eytan M. Stein","doi":"10.1016/j.bneo.2024.100038","DOIUrl":"10.1016/j.bneo.2024.100038","url":null,"abstract":"<div><h3>Abstract</h3><div>The combination of a hypomethylating agent (HMA) and venetoclax (VEN) is approved for adults aged >75 years with newly diagnosed acute myeloid leukemia (AML) as well as those ineligible for intensive chemotherapy (IC). HMA/VEN is increasingly substituted for IC in adults with AML aged <75 years, particularly in those with adverse cytogenetic and molecular features. When patients fail to respond or relapse after HMA/VEN, the utility of salvage IC is largely unknown. We performed a retrospective single-institution study and identified 46 patients who received IC after HMA/VEN, including 24 patients who received HMA/VEN as their first treatment for AML. This population had complete remission (CR)/CR with incomplete count recovery (CRi)/morphologic leukemia-free state rate of 37%, CR/CRi rate of 28%, and a median overall survival (mOS) of 7.2 months (95% confidence interval, 5.0-10.3). Patients who relapsed after an initial response to HMA/VEN and subsequently received IC were more likely to achieve a CR/CRi than those refractory to HMA/VEN (50% vs 19%; <em>P</em> = .04), although there was no statistically significant difference in survival (mOS, 8.8 vs 5.4 months; <em>P</em> = .64). Age >65 years predicted poorer survival (mOS, 4.3 vs 10.6 months; <em>P</em> < .001). IC after HMA/VEN should be further studied and chosen with caution.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy 在AML和CLL/SLL治疗中加入匹伐他汀的1期研究：基于机制的药物再利用策略

Blood Neoplasia Pub Date : 2024-08-28 DOI: 10.1016/j.bneo.2024.100036

Elizabeth A. Brem , Kevin Shieh , Dennis Juarez , Roberta Buono , Deepa Jeyakumar , Susan O’Brien , Thomas H. Taylor , David A. Fruman

引用次数: 0

COVID-19 vaccination in patients with classic and variant hairy cell leukemia 为典型和变异毛细胞白血病患者接种 COVID-19 疫苗

Blood Neoplasia Pub Date : 2024-08-28 DOI: 10.1016/j.bneo.2024.100035

Robert J. Kreitman , Lacey James , Julie Feurtado , Holly Eager , Olena Sierra Ortiz , Mory Gould , Isaac Shpilman , Hong Zhou , Peter D. Burbelo , Jeffrey I. Cohen , Hao-Wei Wang , Constance M. Yuan , Evgeny Arons

{"title":"COVID-19 vaccination in patients with classic and variant hairy cell leukemia","authors":"Robert J. Kreitman , Lacey James , Julie Feurtado , Holly Eager , Olena Sierra Ortiz , Mory Gould , Isaac Shpilman , Hong Zhou , Peter D. Burbelo , Jeffrey I. Cohen , Hao-Wei Wang , Constance M. Yuan , Evgeny Arons","doi":"10.1016/j.bneo.2024.100035","DOIUrl":"10.1016/j.bneo.2024.100035","url":null,"abstract":"<div><h3>Abstract</h3><div>Patients with the B-cell malignancy hairy cell leukemia (HCL) and the poorer-prognosis variant HCLv often receive anti-CD20 monoclonal antibodies (mAbs), which kill normal B cells, impairing humoral immunity. We measured COVID-19 antibodies after doses of COVID-19 vaccine in patients with HCL (n = 415) and HCLv (n = 32). After the second COVID-19 vaccine dose, spike antibody level most strongly correlated with normal B-cell levels (r = 0.365, <em>P</em> < .0001), followed by CD4<sup>+</sup> T-cell count (r = 0.244, <em>P</em> = .0002), and was less related to immunoglobulin G level (r = 0.101, <em>P</em> = .14). Spike antibody also correlated with normal B cells after the third to fifth vaccine doses and with CD4<sup>+</sup> count after the third dose. Normal B-cells were undetectable in 87% of patients within 6 months after the last dose of anti-CD20 mAb and were lower than in patients at 6 to 12 months (<em>P</em> = .0003), which, in turn, were lower than at 12 to 18 months (<em>P</em> = .0002). Infection with COVID-19 became more common after use of the third vaccine dose; spike antibody levels were higher in patients with prior infection (positive vs negative nucleocapsid antibodies; <em>P</em> < .0001). Spike antibodies decreased faster after ibrutinib or anti-CD20 mAb. We conclude that decreased levels of normal B cells in patients with HCL/HCLv, due to disease and/or anti-CD20 therapy, are associated with lower COVID-19 vaccination efficiency and such patients may not respond well to vaccines. The associated studies were registered at <span><span>www.ClinicalTrials.gov</span><svg><path></path></svg></span> as #NCT01087333 (HCL/HCLv) and #NCT04362865 (COVID-19).</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100035"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas 边缘区淋巴瘤的 CD5 表达不能预测较差的预后，与不太活跃的淋巴瘤有相似之处

Blood Neoplasia Pub Date : 2024-07-31 DOI: 10.1016/j.bneo.2024.100031

Paola Ghione , Kurt S. Bantilan , Erel Joffe , M. Lia Palomba , Ariela Noy , Philip Caron , Paul Hamlin , Anita Kumar , Matthew Matasar , Colette Owens , Alison Moskowitz , Lorenzo Falchi , David Straus , Steven Horwitz , Gilles Salles , Ahmet Dogan ∗ , Andrew D. Zelenetz ∗

{"title":"CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas","authors":"Paola Ghione , Kurt S. Bantilan , Erel Joffe , M. Lia Palomba , Ariela Noy , Philip Caron , Paul Hamlin , Anita Kumar , Matthew Matasar , Colette Owens , Alison Moskowitz , Lorenzo Falchi , David Straus , Steven Horwitz , Gilles Salles , Ahmet Dogan ∗ , Andrew D. Zelenetz ∗","doi":"10.1016/j.bneo.2024.100031","DOIUrl":"10.1016/j.bneo.2024.100031","url":null,"abstract":"<div><h3>Abstract</h3><div>The prognostic relevance of CD5 expression in marginal zone lymphoma (MZL) remains poorly characterized. We aimed to compare baseline characteristics and outcomes of patients with CD5<sup>+</sup> MZL and CD5<sup>–</sup> historical matched controls. We hypothesized that patients with CD5<sup>+</sup> MZL may have similarities to other CD5<sup>–</sup> expressing B-cell lymphomas, which may be informative when considering alternative therapeutic approaches for this MZL subgroup. We retrospectively analyzed 64 patients with CD5<sup>+</sup> MZL and 137 CD5<sup>–</sup> MZL controls matched on age at diagnosis and sex. The CD5<sup>+</sup> and CD5<sup>–</sup> cases did not differ in terms of mucosa assiociated lymphoid tissue (MALT)–lymphoma International Prognostic Index or incidence of nodal involvement. Bone marrow involvement was significantly more frequent in CD5<sup>+</sup> patients than in CD5<sup>–</sup> patients (67.5% vs 47.2%; <em>P</em> = .048). Mutated immunoglobulin heavy chain variable region gene was more common in CD5<sup>+</sup> patients (80.0%) than CD5<sup>–</sup> patients (64.0%), but this association was not significant (<em>P</em> = .327). Overall survival was calculated until death from any cause, disease-specific survival until lymphoma-related death, and time from diagnosis to first treatment was calculated either considering all interventions or only systemic treatments. None of these outcomes were associated with CD5 expression.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100031"},"PeriodicalIF":0.0,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142423599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies CD38-CAR 人 NK 细胞与 ATRA 结合使用可增强对表达 CD38 的血液恶性肿瘤的细胞毒性

Blood Neoplasia Pub Date : 2024-07-31 DOI: 10.1016/j.bneo.2024.100032

Ella Troy , Joseph Caporale , Yasemin Sezgin , Marcelo S. F. Pereira , Gregory Behbehani , Justin Lyberger , Dean A. Lee ∗ , Meisam Naeimi Kararoudi ∗

{"title":"CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies","authors":"Ella Troy , Joseph Caporale , Yasemin Sezgin , Marcelo S. F. Pereira , Gregory Behbehani , Justin Lyberger , Dean A. Lee ∗ , Meisam Naeimi Kararoudi ∗","doi":"10.1016/j.bneo.2024.100032","DOIUrl":"10.1016/j.bneo.2024.100032","url":null,"abstract":"<div><h3>Abstract</h3><div>CD38 is a metabolically active enzyme broadly expressed on the surface of normal and malignant hematologic cells. It has been targeted clinically with anti-CD38 monoclonal antibodies (mAbs), for which efficacy may be limited by natural killer (NK)–cell fratricide. Isatuximab is an anti-CD38 mAb that uniquely inhibits CD38 metabolic activity. Here, we used CRISPR/adeno-associated virus (AAV) to generate fratricide–resistant and metabolically–enhanced CD38<sup>KO</sup>/CD38-chimeric antigen receptor (CAR) NK cells using 2 isatuximab-based CD38 single-chain variable fragments (scFvs; reversing heavy and light chain orientation) on the same CD8α/4-1BB/CD3ζ base, and we demonstrate their activity against a range of CD38<sup>+</sup> hematologic malignancies (acute myeloid leukemia, multiple myeloma, Burkitt lymphoma, and T-cell leukemia/lymphoma). The cytotoxicity of the CAR NK cells was enhanced by upregulating CD38 expression on the malignant targets with all-trans retinoic acid (ATRA). By generating CD38<sup>KO</sup>/CD38-CAR T cells using the same engineering approach, we show that the CAR NK cells had higher cytotoxicity than CAR T cells against all hematologic tumor targets. Additionally, AAVS1<sup>KO</sup>/CD38-CAR NK cells were capable of targeting CD38 without experiencing fratricide and have a similar enhanced metabolic activity via the inhibitory activity of the cis-acting isatuximab-based scFv. Finally, we report fratricide-resistant CD38-CAR NK cells with enhanced metabolism and cytotoxicity toward CD38<sup>+</sup> hematologic malignancies, further increased by combination treatment with ATRA.</div></div>","PeriodicalId":100189,"journal":{"name":"Blood Neoplasia","volume":"1 4","pages":"Article 100032"},"PeriodicalIF":0.0,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation 氯法拉滨和氟达拉滨暴露对小儿异基因造血细胞移植术后结果的影响

Blood Neoplasia Pub Date : 2024-07-17 DOI: 10.1016/j.bneo.2024.100030

Linde Dekker , Coco C. H. de Koning , A. Laura Nijstad , Kim C. M. van der Elst , Rick Admiraal , A. Birgitta Versluijs , Jaap Jan Boelens , Alwin D. R. Huitema , Caroline A. Lindemans ∗ , Stefan Nierkens ∗

引用次数: 0

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia 数据驱动的流式细胞仪对老年急性髓性白血病患者的胚泡分化进行分类

Blood Neoplasia Pub Date : 2024-06-19 DOI: 10.1016/j.bneo.2024.100027

Catia Simoes ∗ , Carmen Gonzalez ∗ , François Vergez , Audrey Sarry , Sarah Bertoli , Beñat Ariceta , David Martínez-Cuadrón , Juan-Miguel Bergua , Susana Vives , Lorenzo Algarra , Mar Tormo , Pilar Martinez , Josefina Serrano , Pilar Herrera , Fernando Ramos , Olga Salamero , Esperanza Lavilla , Cristina Gil , Jose-Luis Lopez-Lorenzo , Maria-Belen Vidriales , A.P. De los Santos

引用次数: 0